Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 4
1969 2
1970 1
1972 1
1973 1
1974 1
1976 2
1977 2
1978 3
1979 2
1980 2
1981 5
1982 1
1983 2
1984 3
1985 5
1986 1
1987 2
1988 2
1989 3
1990 2
1991 8
1992 6
1993 3
1994 2
1995 3
1996 3
1997 7
1998 4
1999 4
2000 7
2001 3
2002 2
2003 1
2004 3
2005 2
2006 2
2007 4
2008 6
2009 4
2010 6
2011 5
2012 4
2013 9
2014 6
2015 4
2016 8
2017 4
2018 9
2019 3
2020 7
2021 5
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Results by year

Filters applied: . Clear all
Page 1
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
Chan GC, Chan CM. Chan GC, et al. Biomolecules. 2022 Feb 24;12(3):358. doi: 10.3390/biom12030358. Biomolecules. 2022. PMID: 35327550 Free PMC article. Review.
The newer anti-GD2 strategies, such as bispecific antibody linking of anti-GD2 with activated T cells or chimeric antigen receptor T cells, are currently under clinical trials, and they may become promising alternatives. The use of anti-GD2/GD3 tumor vaccine is a novel and …
The newer anti-GD2 strategies, such as bispecific antibody linking of anti-GD2 with activated T cells or chimeric antigen receptor T cells, …
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM. Shum T, et al. Cancer Discov. 2017 Nov;7(11):1238-1247. doi: 10.1158/2159-8290.CD-17-0538. Epub 2017 Aug 22. Cancer Discov. 2017. PMID: 28830878 Free PMC article.
Providing recombinant or transgenic cytokines may produce the desired benefits but is associated with significant toxicities, constraining clinical use. To circumvent this limitation, we constructed a constitutively signaling cytokine receptor, C7R, which potently triggers …
Providing recombinant or transgenic cytokines may produce the desired benefits but is associated with significant toxicities, constraining …
GD2-targeted immunotherapy and radioimmunotherapy.
Dobrenkov K, Cheung NK. Dobrenkov K, et al. Semin Oncol. 2014 Oct;41(5):589-612. doi: 10.1053/j.seminoncol.2014.07.003. Epub 2014 Jul 21. Semin Oncol. 2014. PMID: 25440605 Free PMC article. Review.
Anti-GD2 antibody is now incorporated into the standard of care for the treatment of high-risk metastatic neuroblastoma. Building on this experience, novel combinations of antibodies, cytokines, cells, and genetically engineered products all directed at GD2 are rapi …
Anti-GD2 antibody is now incorporated into the standard of care for the treatment of high-risk metastatic neuroblastoma. Build …
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.
Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, Donzelli M, Wolden SL, Haque S, Dunkel I, Souweidane MM, Greenfield JP, Tickoo S, Lewis JS, Lyashchenko SK, Carrasquillo JA, Chu B, Horan C, Larson SM, Cheung NV, Modak S. Kramer K, et al. J Hematol Oncol. 2022 Nov 12;15(1):165. doi: 10.1186/s13045-022-01383-4. J Hematol Oncol. 2022. PMID: 36371226 Free PMC article. Clinical Trial.
RESULTS: Thirty-eight patients received 100 radioiodinated omburtamab injections. Diagnoses included metastatic neuroblastoma (n = 16) and other B7H3-expressing solid tumors (n = 22). ...CONCLUSIONS: cRIT with (131)I-omburtamab is safe, has favorable dosimetry and m …
RESULTS: Thirty-eight patients received 100 radioiodinated omburtamab injections. Diagnoses included metastatic neuroblastoma …
Neuroblastoma: Essential genetic pathways and current therapeutic options.
Salemi F, Alam W, Hassani MS, Hashemi SZ, Jafari AA, Mirmoeeni SMS, Arbab M, Mortazavizadeh SMR, Khan H. Salemi F, et al. Eur J Pharmacol. 2022 Jul 5;926:175030. doi: 10.1016/j.ejphar.2022.175030. Epub 2022 May 20. Eur J Pharmacol. 2022. PMID: 35605657 Review.
Neuroblastoma is a very diverse pediatric tumor that starts from the neural crest, and it is responsible over more than 15% of all juvenile cancer deaths. Clinical signs and symptoms are highly dependent on tumor origin and spread. Bone, lymph nodes, liver, intracranial an …
Neuroblastoma is a very diverse pediatric tumor that starts from the neural crest, and it is responsible over more than 15% of all juvenile …
Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S, Cheung NK. Modak S, et al. Cancer Invest. 2007 Feb;25(1):67-77. doi: 10.1080/07357900601130763. Cancer Invest. 2007. PMID: 17364560 Review.
Achieving a cure for metastatic neuroblastoma remains a challenge despite sensitivity to chemotherapy and radiotherapy. ...Such markers will allow further optimization of other anti-MRD therapies. We review the current status of anti-GD2 clinical trials for n …
Achieving a cure for metastatic neuroblastoma remains a challenge despite sensitivity to chemotherapy and radiotherapy. ...Suc …
Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P, Jeremic M, Jeremic R, Dusanovic Pjevic M, Rasic M, Djuricic SM, Milickovic M, Vukadin M, Mijovic T, Savic D. Rasic P, et al. Molecules. 2023 Apr 11;28(8):3356. doi: 10.3390/molecules28083356. Molecules. 2023. PMID: 37110590 Free PMC article. Review.
Moreover, B7-H3-targeting chimeric antigen receptor (CAR)-T cells demonstrated significant in vivo activity against different xenograft models of neuroblastoma, Ewing sarcoma, and osteosarcoma. Finally, clinical studies demonstrated the potent anti-tumor activity of B7-H3- …
Moreover, B7-H3-targeting chimeric antigen receptor (CAR)-T cells demonstrated significant in vivo activity against different xenograft mode …
Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
Mastrangelo S, Rivetti S, Triarico S, Romano A, Attinà G, Maurizi P, Ruggiero A. Mastrangelo S, et al. Int J Mol Sci. 2021 Nov 23;22(23):12648. doi: 10.3390/ijms222312648. Int J Mol Sci. 2021. PMID: 34884452 Free PMC article. Review.
Prognosis of metastatic neuroblastoma is very poor. Its treatment includes induction chemotherapy, surgery, high-dose chemotherapy, radiotherapy, and maintenance with retinoic acid, associated with the anti-GD2 monoclonal antibody (ch14.18) dinutuximab. ...
Prognosis of metastatic neuroblastoma is very poor. Its treatment includes induction chemotherapy, surgery, high-dose chemothe …
Establishment and characterization of new orthotopic and metastatic neuroblastoma models.
Daudigeos-Dubus E, LE Dret L, Rouffiac V, Bawa O, Leguerney I, Opolon P, Vassal G, Geoerger B. Daudigeos-Dubus E, et al. In Vivo. 2014 Jul-Aug;28(4):425-34. In Vivo. 2014. PMID: 24982206
BACKGROUND/AIM: Treatment of metastatic neuroblastoma remains a challenge in pediatric oncology. ...
BACKGROUND/AIM: Treatment of metastatic neuroblastoma remains a challenge in pediatric oncology. ...
Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.
Berthold F, Spix C, Kaatsch P, Lampert F. Berthold F, et al. Paediatr Drugs. 2017 Dec;19(6):577-593. doi: 10.1007/s40272-017-0251-3. Paediatr Drugs. 2017. PMID: 28786082 Free PMC article.
BACKGROUND: A comprehensive clinical long-term survey over the complete spectrum of neuroblatoma disease is lacking in the literature. OBJECTIVE: Our objective was to describe the incidence, risk profiles, therapies, and outcomes for the total cohort of German patients wit …
BACKGROUND: A comprehensive clinical long-term survey over the complete spectrum of neuroblatoma disease is lacking in the literature …
187 results